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The methodology that we use for 34bE12 antibody is different from that used by Wheeler et al, 1 beginning with section thickness. We do not use 6 mm sections for any immunostaining procedure in contrast to the study by Wheeler et al. Indeed, it is not uncommon for a multitude of protocols to exist for any given antibody across laboratories.
The methodology that we use in our laboratory has been optimized and validated against tissues and controls with the Benchmark XT (Ventana Medical Systems, Tuscon, AZ, USA), and the results have been quite satisfactory in our diagnostic experience. We have not optimized 34bE12 antibody in our laboratory for detecting lobular carcinomas, because 34bE12 is an antibody that detects a highmolecular-weight cytokeratin that ultrastructurally correlates with the presence of tonofilaments. Tonofilaments are present in carcinomas of any duct derivation in addition to squamous cell carcinomas. 2 We detected 34bE12 in 50% of lobular carcinomas (10 cases examined) vs 80% in the paper by Wheeler et al (5 cases examined). The paper by Wheeler et al also clearly demonstrates that 34bE12 is not useful in the distinction of tubulolobular (93% positive) vs lobular carcinomas (80% positive). E-cadherin alone is a superior antibody for the distinction of ductal vs lobular phenotypes.
It was not the intent of our paper to discuss the usefulness of 34bE12 in making the diagnosis of lobular carcinoma. Rather, our goal was to demonstrate
